Open AccessCost-utility analysis of adding abiraterone acetate plus prednisone/prednisolone to long-term hormone therapy in newly diagnosed advanced prostate cancer in England: Lifetime decision model based on STAMPEDE trial data
Author(s) -
Caroline S. Clarke,
Rachael Hunter,
Andrea Gabrio,
Christopher D. Brawley,
Fiona C. Ingleby,
David P. Dearnaley,
David Matheson,
Gerhardt Attard,
Hannah Rush,
Robert J. Jones,
William Cross,
Chris Parker,
Martin Russell,
Robin Millman,
Silke Gillessen,
Zafar Malik,
J.F. Lester,
James Wylie,
Noel W. Clarke,
Mahesh Parmar,
Matthew R. Sydes,
Nicholas D. James
Publication year - 2022
Publication title -
plos one
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.99
H-Index - 332
ISSN - 1932-6203
DOI - 10.1371/journal.pone.0269192
Subject(s) - abiraterone acetate , prednisone , prostate cancer , prednisolone , medicine , abiraterone , oncology , term (time) , bioinformatics , cancer , androgen deprivation therapy , biology , androgen receptor , physics , quantum mechanics